Univercells SA raises €44m in first close of its Series D

In addition to the support of existing public institutional funds such as SFPI-FPIM (Société Fédérale de Participation et d‘Investissement), SRIW (Société Régionale d‘Investissement de Wallonie) and the Amerigo
Fund, other historical investors joined the round and consolidated their participation in Univercells, including Adjuvant Capital, AdBio Partners, and TheClubDeal, among others, and new investors including 3d investors; Global Health Investment Corporation, and In-Q-Tel.

Finally, a call was launched in the summer of 2022 to all collaborators of the Univercells Group,
offering the possibility to invest. The initiative was successful beyond expectations and will
contribute to the growth of the Group, while reinforcing the engagement of all colleagues.
The proceeds will mainly support the development of Quantoom Biosciences‘ RNA platform,
complementing funds from the Bill & Melinda Gates Foundation and the Walloon Region
(DGO6), the commercial expansion of Exothera‘s Jumet-based infrastructure, and the
global growth of the Univercells Group.